Clinical Trial: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Brief Summary:

Background:

  • Improved treatments for a variety of treatment-resistant, CD30-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed.
  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.
  • Autologous T cells genetically modified to express CARs targeting the B-cell antigen CD19 have caused complete remissions in a small number of patients with lymphoma. These results demonstrate that CAR-expressing T cells can have anti-lymphoma activity in humans.
  • CD30 expression can be easily detected by immunohistochemistry on lymphoma cells, which allows selection of CD30-expressing malignancies for treatment.
  • CD30 is not known to be expressed by normal cells except for a small number of activated lymphocytes and decidual cells in the pregnant uterus.
  • We have constructed a novel fully-human anti-CD30 CAR that can specifically recognize CD30-expressing target cells in vitro and eradicate CD30-expressing tumors in mice.
  • This particular CAR has not been tested before in humans.
  • Possible toxicities include cytokine-associated toxicities such as fever, hypotension, and neurological toxicities. Elimination of a small number of normal activated lymphocytes is possible, and unknown toxicities are also possible.

Objectives:

Primary

-Determine the safety and feasibility of administering T-cells expressing a novel f

Detailed Summary:

Background:

  • Improved treatments for a variety of treatment-resistant, CD30-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed.
  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.
  • Autologous T cells genetically modified to express CARs targeting the B-cell antigen CD19 have caused complete remissions in a small number of patients with lymphoma. These results demonstrate that CAR-expressing T cells can have anti-lymphoma activity in humans.
  • CD30 expression can be easily detected by immunohistochemistry on lymphoma cells, which allows selection of CD30-expressing malignancies for treatment.
  • CD30 is not known to be expressed by normal cells except for a small number of activated lymphocytes and decidual cells in the pregnant uterus.
  • We have constructed a novel fully-human anti-CD30 CAR that can specifically recognize CD30-expressing target cells in vitro and eradicate CD30-expressing tumors in mice.
  • This particular CAR has not been tested before in humans.
  • Possible toxicities include cytokine-associated toxicities such as fever, hypotension, and neurological toxicities. Elimination of a small number of normal activated lymphocytes is possible, and unknown toxicities are also possible.

Objectives:

Primary

-Determine the safety and feasibility of administering T-cells expressing a novel f
Sponsor: National Cancer Institute (NCI)

Current Primary Outcome: Determine the safety and feasibility of administering T cells expressing a novel fully-human anti-CD30 CAR to patients with advanced CD30-expresssing lymphomas. [ Time Frame: 4-5 weeks after first dose ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Evaluate the in vivo persistence and peak blood levels of anti-CD30 CAR T cells after initial and repeated CAR T-cell infusions [ Time Frame: 5 years ]
  • Assess for evidence of antilymphoma activity by anti-CD30 CAR T cells [ Time Frame: 5 years ]


Original Secondary Outcome: Same as current

Information By: National Institutes of Health Clinical Center (CC)

Dates:
Date Received: February 9, 2017
Date Started: January 23, 2017
Date Completion: June 30, 2021
Last Updated: April 11, 2017
Last Verified: February 16, 2017